The Korean Journal of Physiology and Pharmacology

The Korean Society of Pharmacology (대한약리학회)
권호 표지

Janus Kinase 2 Inhibitor AG490 Inhibits the STAT3 Signaling Pathway by Suppressing Protein Translation of gp130

  • Seo, In-Ae (Department of Physiology, College of Medicine, Dong-A University) ;
  • Lee, Hyun-Kyoung (Department of Physiology, College of Medicine, Dong-A University) ;
  • Shin, Yoon-Kyung (Department of Physiology, College of Medicine, Dong-A University) ;
  • Lee, Sang-Hwa (Department of Microbiology, College of Medicine, Dong-A University) ;
  • Seo, Su-Yeong (Department of Microbiology, College of Medicine, Dong-A University) ;
  • Park, Ji-Wook (Department of Neurology, Medical Science Research Institute, College of Medicine, Dong-A University) ;
  • Park, Hwan-Tae (Department of Physiology, College of Medicine, Dong-A University)
  • Published : 2009.04.30
Download PDF
⟨ Previous Next ⟩

Abstract

The binding of interleukin-6 (IL-6) cytokine family ligands to the gp130 receptor complex activates the Janus kinase (JAK)/ signal transducer and activator of transcription 3 (STAT3) signal transduction pathway, where STA T3 plays an important role in cell survival and tumorigenesis. Constitutive activation of STAT3 has been frequently observed in many cancer tissues, and thus, blocking of the gp130 signaling pathway, at the JAK level, might be a useful therapeutic approach for the suppression of STAT3 activity, as anticancer therapy. AG490 is a tyrphostin tyrosine kinase inhibitor that has been extensively used for inhibiting JAK2 in vitro and in vivo. In this study, we demonstrate a novel mechanism associated with AG490 that inhibits the JAK/STAT3 pathway. AG490 induced downregulation of gp130, a common receptor for the IL-6 cytokine family compounds, but not JAK2 or STAT3, within three hours of exposure. The downregulation of gp130 was not caused by enhanced degradation of gp130 or by inhibition of mRNA transcription. It most likely occurred by translation inhibition of gp130 in association with phosphorylation of the eukaryotic initiation factor-2 a. The inhibition of protein synthesis of gp130 by AG490 led to immediate loss of mature gp130 in cell membranes, due to its short half-life, thereby resulting in reduction in the STAT3 response to IL-6. Taken together, these results suggest that AG490 blocks the STAT3 activation pathway via a novel pathway.

Keywords

References

  1. Aggarwal BB, Sethi G, Ahn KS, Sandur SK, Pandey MK, Kunnumakkara AB, Sung B, Ichikawa H. Targeting signal- transducer- and-activator-of-transcription (STAT)-3 for prevention and therapy of cancer: modern target but ancient solution. Ann N Y Acad Sci 1091: 151−169, 2006 https://doi.org/10.1196/annals.1378.063
  2. Battle TE, Frank DA. The role of STATs in apoptosis. Curr Mol Med 2: 381−392, 2002 https://doi.org/10.2174/1566524023362456
  3. Bertolotti A, Zhang Y, Hendershot LM, Harding HP, Ron D. Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response. Nat Cell Biol 2: 326−332, 2000 https://doi.org/10.1038/35014014
  4. Ferrajoli A, Faderl S, Van Q, Koch P, Harris D, Liu Z, Hazan- Halevy I, Wang Y, Kantarjian HM, Priebe W, Estrov Z. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells. Cancer Res 67: 11291−11299, 2009 https://doi.org/10.1158/0008-5472.CAN-07-0593
  5. Gerhartz C, Dittrich E, Stoyan T, Rose-John S, Yasukawa K, Heinrich PC, Graeve L. Biosynthesis and half-life of the interleukin-6 receptor and its signal transducer gp130. Eur J Biochem 223: 265−274, 1994 https://doi.org/10.1111/j.1432-1033.1994.tb18991.x
  6. Germain D, Frank DA. Targeting the cytoplasmic and nuclear functions of signal transducers and activators of transcription 3 for cancer therapy. Clin Cancer Res 13: 5665−5669, 2007 https://doi.org/10.1158/1078-0432.CCR-06-2491
  7. Graf D, Haselow K, Munks I, Bode JG, Haussinger D. Caspase- mediated cleavage of the signal-transducing IL-6 receptor subunit gp130. Arch Biochem Biophys 477: 330−338, 2008 https://doi.org/10.1016/j.abb.2008.06.009
  8. Graf D, Kohlmann C, Haselow K, Gehrmann T, Bode JG, Haussinger D. Bile acids inhibit interleukin-6 signaling via gp130 receptor-dependent and -independent pathways in rat liver. Hepatology 44: 1206−1217, 2006 https://doi.org/10.1002/hep.21368
  9. Harding HP, Zhang Y, Ron D. Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase. Nature 397: 271−274, 1999 https://doi.org/10.1038/16729
  10. Heinrich PC, Behrmann I, Haan S, Hermanns HM, M$\ddot{u}$ller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J 374: 1−20, 2003 https://doi.org/10.1042/BJ20030407
  11. Hideshima T, Chauhan D, Hayashi T, Akiyama M, Mitsiades N, Mitsiades C, Podar K, Munshi NC, Richardson PG, Anderson KC. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene 22: 8386−8393, 2003 https://doi.org/10.1038/sj.onc.1207170
  12. Lauta VM. Interleukin-6 and the network of several cytokines in multiple myeloma: an overview of clinical and experimental data. Cytokine 16: 79−86, 2001 https://doi.org/10.1006/cyto.2001.0982
  13. Lee HK, Seo IA, Suh DJ, Lee HJ, Park HT. A novel mechanism of methylglyoxal cytotoxicity in neuroglial cells. J Neurochem 108: 273−284, 2009a https://doi.org/10.1111/j.1471-4159.2008.05764.x
  14. Lee HK, Seo IA, Shin YK, Park JW, Suh DJ, Park HT. Capsaicin inhibits the IL-6/STAT3 pathway by depleting intracellular gp130 pools through endoplasmic reticulum stress. Biochem Biophys Res Commun 382: 445−450, 2009c https://doi.org/10.1016/j.bbrc.2009.03.046
  15. Lee HK, Seo IA, Suh DJ, Hong JI, Yoo YH, Park HT. Interleukin-6 is required for the early induction of glial fibrillary acidic protein in Schwann cells during Wallerian degeneration. J Neurochem 108: 776−786, 2009b https://doi.org/10.1111/j.1471-4159.2008.05826.x
  16. Meydan N, Grunberger T, Dadi H, Shahar M, Arpaia E, Lapidot Z, Leeder JS, Freedman M, Cohen A, Gazit A, Levitzki A, Roifman CM. Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature 379: 645−648, 1996 https://doi.org/10.1038/379645a0
  17. Miyamoto N, Sugita K, Goi K, Inukai T, Lijima K, Tezuka T, Kojika S, Nakamura M, Kagami K, Nakazawa S. The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome. Leukemia 15: 1758−1768, 2001
  18. Opdam FJ, Kamp M, de Bruijn R, Roos E. Jak kinase activity is required for lymphoma invasion and metastasis. Oncogene 23: 6647−6653, 2004 https://doi.org/10.1038/sj.onc.1207887
  19. Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. Oncogene 55: 8404−8413, 2002
  20. Samanta AK, Lin H, Sun T, Kantarjian H, Arlinghaus RB. Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res 66: 6468−6472, 2006 https://doi.org/10.1158/0008-5472.CAN-06-0025
  21. Satriotomo I, Bowen KK, Vemuganti R. JAK2 and STAT3 activation contributes to neuronal damage following transient focal cerebral ischemia. J Neurochem 98: 1353−1368, 2006 https://doi.org/10.1111/j.1471-4159.2006.04051.x
  22. Scholz A, Heinze S, Detjen KM, Peters M, Welzel M, Hauff P, Schirner M, Wiedenmann B, Rosewicz S. Activated signal transducer and activator of transcription 3 (STAT3) supports the malignant phenotype of human pancreatic cancer. Gastroenterology 125: 891−905, 2003 https://doi.org/10.1016/S0016-5085(03)01064-3
  23. Shyu WC, Lin SZ, Chiang MF, Chen DC, Su CY, Wang HJ, Liu RS, Tsai CH, Li H. Secretoneurin promotes neuroprotection and neuronal plasticity via the Jak2/Stat3 pathway in murine models of stroke. J Clin Invest 118: 133−148, 2008 https://doi.org/10.1172/JCI32723
  24. Szegezdi E, Logue SE, Gorman AM, Samali A. Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep 7: 880−885, 2006 https://doi.org/10.1038/sj.embor.7400779
  25. Tanaka Y, Tanaka N, Saeki Y, Tanaka K, Murakami M, Hirano T, Ishii N, Sugamura K. c-Cbl-dependent monoubiquitination and lysosomal degradation of gp130. Mol Cell Biol 28: 4805−4818, 2008 https://doi.org/10.1128/MCB.01784-07
  26. Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, Clay FJ, Malki S, Alderman BM, Grail D, Hollande F, Heath JK, Ernst M. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat Med 8: 1089−1097, 2002 https://doi.org/10.1038/nm763
  27. Verstovsek S, Manshouri T, Quintás-Cardama A, Harris D, Cortes J, Giles FJ, Kantarjian H, Priebe W, Estrov Z. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation. Clin Cancer Res 14: 788−796, 2008 https://doi.org/10.1158/1078-0432.CCR-07-0524
  28. Weissenberger J, Loeffler S, Kappeler A, Kopf M, Lukes A, Afanasieva TA, Aguzzi A, Weis J. IL-6 is required for glioma development in a mouse model. Oncogene 23: 3308−3316, 2004 https://doi.org/10.1038/sj.onc.1207455